CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Nigel Clerkin

Chief Financial Officer, Icon

Search every verified Nigel Clerkin interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Nigel Clerkin, Chief Financial Officer at ICON, discussed the company's financial performance during the Q2 and Q3 2025 earnings calls. He noted that revenue in Q2 2025 was $2.017 billion, a year-on-year decrease of 4.8%, and reported adjusted gross margin of 28.3% for the quarter, compared to 29.9% in Q2 2024. Clerkin attributed recent revenue guidance changes primarily to an increased proportion of pass-through costs in the revenue mix, stating that foreign exchange impacts were neutral. He also said that the rising share of pass-throughs was weighing on margin outlook for the remainder of 2025 and into 2026. Clerkin addressed questions about gross margins and pricing, acknowledging that the increasing composition of pass-throughs and a tougher pricing environment were factors affecting future margins. He stated that the company was not providing specific margin guidance for the next year at that time, citing the need to assess mitigating factors. He also emphasized the company's ability to leverage its scale in customer conversations and its philosophy of sharing benefits with clients through more effective and efficient service delivery.

Recent appearances

  • $ICLR ICON Public Q3 2025 Earnings Conference Call

    October 23, 2025 · 📺 EARNMOAR

    10/23/2025 Q&A: 15:40 ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical t…

    Watch on YouTube ↗

  • $ICLR ICON Public Limited Q2 2025 Earnings Conference Call

    July 24, 2025 · 📺 EARNMOAR

    07/24/2025 Q&A: 17:46 ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical t…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →